Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Neurotech
company
About
Neurotech is a biotechnology company developing sight-saving therapeutics for chronic retinal diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $35M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 1995
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases—including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$35M
Neurotech has raised a total of
$35M
in funding over 2 rounds. Their latest funding was raised on
Nov 16, 2006 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 16, 2006 | Series B | $35M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Neurotech is funded by 3 investors.
Mayflower
and Triginta Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
Triginta Capital
|
— | Series B |
Versant Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
